Binding sites for prostaglandin F2 alpha in human corpora lutea. 1983

S Tanaka, and Y Shimoya, and M Hamamatsu, and M Hashimoto

UI MeSH Term Description Entries
D008183 Luteal Phase The period in the MENSTRUAL CYCLE that follows OVULATION, characterized by the development of CORPUS LUTEUM, increase in PROGESTERONE production by the OVARY and secretion by the glandular epithelium of the ENDOMETRIUM. The luteal phase begins with ovulation and ends with the onset of MENSTRUATION. Menstrual Cycle, Luteal Phase,Menstrual Cycle, Secretory Phase,Menstrual Secretory Phase,Postovulatory Phase,Phase, Luteal,Phase, Postovulatory,Secretory Phase, Menstrual
D011460 Prostaglandins F (9 alpha,11 alpha,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha)); (5Z,9 alpha,11,alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (PGF(2 alpha)); (5Z,9 alpha,11 alpha,13E,15S,17Z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring PGF have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics. PGF
D002458 Cell Fractionation Techniques to partition various components of the cell into SUBCELLULAR FRACTIONS. Cell Fractionations,Fractionation, Cell,Fractionations, Cell
D003338 Corpus Luteum The yellow body derived from the ruptured OVARIAN FOLLICLE after OVULATION. The process of corpus luteum formation, LUTEINIZATION, is regulated by LUTEINIZING HORMONE. Corpora Lutea,Lutea, Corpora
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D015237 Dinoprost A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions. PGF2,PGF2alpha,Prostaglandin F2,Prostaglandin F2alpha,9alpha,11beta-PGF2,Enzaprost F,Estrofan,PGF2 alpha,Prostaglandin F2 alpha,9alpha,11beta PGF2,F2 alpha, Prostaglandin,F2alpha, Prostaglandin,alpha, PGF2

Related Publications

S Tanaka, and Y Shimoya, and M Hamamatsu, and M Hashimoto
June 1977, The Journal of clinical endocrinology and metabolism,
S Tanaka, and Y Shimoya, and M Hamamatsu, and M Hashimoto
January 1982, Methods in enzymology,
S Tanaka, and Y Shimoya, and M Hamamatsu, and M Hashimoto
January 1979, Molecular and cellular endocrinology,
S Tanaka, and Y Shimoya, and M Hamamatsu, and M Hashimoto
August 1976, Biology of reproduction,
S Tanaka, and Y Shimoya, and M Hamamatsu, and M Hashimoto
March 1981, The Journal of endocrinology,
S Tanaka, and Y Shimoya, and M Hamamatsu, and M Hashimoto
October 1987, Biology of reproduction,
S Tanaka, and Y Shimoya, and M Hamamatsu, and M Hashimoto
October 1994, Prostaglandins,
S Tanaka, and Y Shimoya, and M Hamamatsu, and M Hashimoto
August 1980, European journal of biochemistry,
S Tanaka, and Y Shimoya, and M Hamamatsu, and M Hashimoto
May 1988, Journal of animal science,
Copied contents to your clipboard!